Perrigo NicoPatch OTC nicotine patch in development under Elan joint venture.
• By The Tan Sheet
PERRIGO OTC NICOTINE PATCH TARGETED FOR 1998 LAUNCH, according to company materials distributed recently to the retail trade. The store brand patch is the product of a joint venture between Perrigo and Elan Pharmaceuticals, the developer of the ProStep patch, which is marketed as a prescription smoking cessation aid by Lederle. Approval of Elan's NDA for the OTC product is expected in the first half of 1998. Perrigo is aiming for a late spring/early summer launch.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.
Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.
A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.